Resveratrol relieves the impaired inflammatory responses of MPO-deficient primary mixed glia to rotenone exposure.

<p><b>A.</b> Primary mixed glial cells from <i>Mpo^−/−</i> mice were mock-treated or treated with the indicated concentrations of resveratrol (RESV) for 1 h before exposure to 30 nM rotenone (Rot) for 24 h, and the supernatants were assayed for nitrate concentration. The results are the fold changes in mean ± SD of three experiments performed in triplicate.*<i>P<0.05,</i> **<i>P<0.01</i> when compared with rotenone-treated cells. <b>B.</b> Primary mixed glial cells from <i>Mpo^−/−</i> mice were mock-treated or treated with 20 µM resveratrol prior exposure to 30 nM rotenone. The levels of IL-1β, COX-2 and TNF-α mRNA in primary mixed glia from <i>Mpo^−/−</i> mice were determined by RT-PCR-based analyses. The data are representative of more than three independent experiments. <b>C–D.</b> Primary mixed glial cells from <i>Mpo^−/−</i> mice were incubated with the indicated concentrations of resveratrol and/or rotenone for 3 days. Cell viability was determined using the LDH assay (<b>C</b>) and the CCK-8 assay (<b>D</b>). Data were expressed as the percentage of cell death or cell viability to mock-treated cells from more than three independent experiments (<b>C</b> and <b>D</b>, respectively). *<i>P<0.05,</i> **<i>P<0.01</i> when compared with rotenone-treated cells.